ライフサイエンスコーパス: Epstein-Barr virus

1 a common DNA virus that is related to human Epstein-Barr virus.

2 virus, norovirus, rotavirus, parvovirus, and Epstein-Barr virus.

3 LTL attrition, with no association found for Epstein-Barr virus.

4 ovirus, adenovirus, human herpesvirus 6, and Epstein-Barr virus.

5 lla zoster virus, human cytomegalovirus, and Epstein-Barr virus.

6 27 with cytomegalovirus (26.5%), and 1 with Epstein-Barr virus (1%).

7 s 1 (HSV-1) were 9% in saliva and 5% in GCF; Epstein-Barr virus 36% in saliva and 39% in GCF; human c

8 peptides from MS-associated foreign agents (Epstein-Barr virus and Akkermansia muciniphila), and aut

9 -protein interactions (PPI) networks between Epstein-Barr virus and Homo sapiens.

10 deceased newborn tested positive by qPCR for Epstein-Barr virus and human herpesvirus 6, including th

11 that infection with some viruses, including Epstein-Barr virus and influenza virus can elicit T cell

12 papillomaviruses and the gammaherpesviruses Epstein-Barr virus and Kaposi's sarcoma-associated herpe

13 el suitable for study of the human pathogens Epstein-Barr virus and Kaposi's sarcoma-associated herpe

14 These data demonstrate that Epstein-Barr virus and possible other double-stranded DN

15 t by immortalization of thymic B cells using Epstein-Barr virus and TLR9 activation.

16 simplex, varicella zoster, cytomegalovirus, Epstein-Barr virus and Toxoplasma gondii in patients wit

17 ommon viral targets include cytomegalovirus, Epstein-Barr virus, and adenovirus, though recent publis

18 Epstein-Barr virus, another herpesvirus, has two propert

19 nts with Alzheimer's disease to two separate Epstein-Barr virus antigens.

20 several bacterial and viral taxa, including Epstein-Barr virus, as well as animal and plant DNA, whi

21 To this end, we report a self-replicating Epstein-Barr virus-based episomal vector for the long-te

22 uman herpesvirus 6B, HHV-6A, adenovirus, and Epstein-Barr virus between days 0 and 100 post-HCT.

23 , 1 CSF specimen was positive for EV-D68 and Epstein-Barr virus by real-time polymerase chain reactio

24 Chronic active Epstein-Barr virus (CAEBV) presents with high levels of

25 Many double-stranded DNA viruses, such as Epstein-Barr virus, can establish persistent infection,

26 persons positive for IgG antibodies against Epstein-Barr virus capsid antigen, 215 positive for thyr

27 l carcinoma cells results in almost complete Epstein-Barr virus clearance.

28 at least 1 positive viremia during follow-up.Epstein-Barr virus D+/R- patients (P = 0.046) as well as

29 In the 328 patients with data for Epstein-Barr virus DNA, a detectable viral DNA titre was

30 d at constructing a composite score based on Epstein-Barr virus DNAemia (EBVd) and simple clinical an

31 Epstein Barr virus (EBV) is the etiologic agent involved

32 , TSPyV, HPyV9, HPyV10) and 5 herpesviruses (Epstein Barr virus (EBV), cytomegalovirus (CMV), herpes

33 pients and is most often associated with the Epstein Barr virus (EBV).

34 la virus (EBOV), influenza A virus (IAV) and Epstein Barr virus (EBV).

35 2%), human herpesvirus 7 (HHV-7) (20.5%) and Epstein-Barr virus (EBV) (16.4%) were highly prevalent i

36 The human gammaherpesvirus Epstein-Barr virus (EBV) (human herpesvirus 4 [HHV4]) in

37 uman herpes virus (HHV)-6, HHV-7, chlamydia, Epstein-Barr virus (EBV) and bacterial 16S ribosomal DNA

38 to CD8 T cells specific for control viruses, Epstein-Barr virus (EBV) and cytomegalovirus (CMV), and

39 ither method, whereas other viruses, such as Epstein-Barr virus (EBV) and cytomegalovirus (CMV), were

40 s demonstrating a link between B cell-tropic Epstein-Barr virus (EBV) and disease onset.

41 The human tumor viruses Epstein-Barr virus (EBV) and Kaposi sarcoma-associated h

42 circular RNAs (circRNAs) expressed from the Epstein-Barr virus (EBV) and Kaposi's sarcoma herpesviru

43 The gammaherpesviruses Epstein-Barr virus (EBV) and Kaposi's sarcoma-associated

44 IMPORTANCE The two human gammaherpesviruses, Epstein-Barr virus (EBV) and Kaposi's sarcoma-associated

45 Both Epstein-Barr virus (EBV) and Kaposi's sarcoma-associated

46 The human gammaherpesviruses Epstein-Barr virus (EBV) and Kaposi's sarcoma-associated

47 ong all of the known biological carcinogens, Epstein-Barr virus (EBV) and Kaposi's sarcoma-associated

48 Clinically available drugs active against Epstein-Barr virus (EBV) and other human herpesviruses a

49 ic Burkitt lymphoma (eBL) is associated with Epstein-Barr virus (EBV) and Plasmodium falciparum malar

50 monella enterica, Aspergillus fumigatus, and Epstein-Barr virus (EBV) and samples from tuberculosis p

51 y with decitabine can upregulate immunogenic Epstein-Barr virus (EBV) antigens on Burkitt lymphoma (B

52 between polyomavirus JC (JC virus [JCV]) and Epstein-Barr virus (EBV) at sequences of JCV found infec

53 Mature human B cells infected by Epstein-Barr virus (EBV) become activated, grow, and pro

54 e NEC, namely the 1.56 angstrom structure of Epstein-Barr virus (EBV) BFRF1-BFLF2, as well as an incr

55 We have found that the Epstein-Barr virus (EBV) BGLF2 tegument protein binds to

56 The Epstein-Barr virus (EBV) BHLF1 gene encodes an abundant

57 an herpesviruses, cytomegalovirus (HCMV) and Epstein-Barr virus (EBV) both impair the activity of APC

58 Epstein-Barr virus (EBV) can efficiently establish stabl

59 Epstein-Barr virus (EBV) causes B cell lymphomas and tra

60 As the first discovered human cancer virus, Epstein-Barr virus (EBV) causes Burkitt's lymphoma and n

61 Infection of T cells by Epstein-Barr virus (EBV) causes chronic active EBV infec

62 Epstein-Barr virus (EBV) causes endemic Burkitt lymphoma

63 Epstein-Barr virus (EBV) causes infectious mononucleosis

64 Epstein-Barr virus (EBV) causes infectious mononucleosis

65 ting tumor cells (CTCs) and plasma levels of Epstein-Barr virus (EBV) DNA are sensitive prognostic to

66 n each sample, we measured levels of CMV and Epstein-Barr virus (EBV) DNA by droplet digital PCR (ddP

67 In particular, plasma Epstein-Barr virus (EBV) DNA has been used for populatio

68 sorder (HVLPD) typically have high levels of Epstein-Barr virus (EBV) DNA in T cells and/or natural k

69 Total CMV and Epstein-Barr virus (EBV) DNA were quantified in peripher

70 Epstein-Barr virus (EBV) DNAemia is a major risk factor

71 Epstein-Barr virus (EBV) encodes >44 viral microRNAs (mi

72 -1), HSV-2, human cytomegalovirus (HCMV) and Epstein-Barr virus (EBV) entry glycoproteins have define

73 Epstein-Barr virus (EBV) entry into epithelial cells is

74 The Epstein-Barr virus (EBV) episome is known to interact wi

75 's sarcoma-associated herpesvirus (KSHV) and Epstein-Barr Virus (EBV) establish life-long infections

76 Epstein-Barr virus (EBV) establishes a stable latent inf

77 Epstein-Barr virus (EBV) establishes latent infections a

78 Epstein-Barr virus (EBV) establishes lifelong infection

79 Epstein-Barr virus (EBV) genomes persist in latently inf

80 The Epstein-Barr virus (EBV) gp350 glycoprotein interacts wi

81 for both T- and B-cell infection.IMPORTANCE Epstein-Barr virus (EBV) has a well-described tropism fo

82 Epstein-Barr virus (EBV) has been implicated in lymphoma

83 stricted to the replication cycle.IMPORTANCE Epstein-Barr virus (EBV) has significant oncogenic poten

84 IgA antibodies targeting Epstein-Barr virus (EBV) have been proposed for screenin

85 al cells in infection and persistence of the Epstein-Barr virus (EBV) have long been difficult to res

86 The Epstein-Barr virus (EBV) immediate early transactivator

87 omprehensive EBV regulome in LCLs.IMPORTANCE Epstein-Barr virus (EBV) immortalization of resting B ly

88 om anal samples; 2.7% (95% CI: 0.7-4.7%) for Epstein-Barr virus (EBV) immunoglobulin M (IgM) positivi

89 The discovery of Epstein-Barr virus (EBV) in 1964 gave birth to the field

90 ally permissive phenotype of the herpesvirus Epstein-Barr virus (EBV) indicate that upon exposure to

91 Both the loss of immunoregulation of Epstein-Barr virus (EBV) infected cells, as well as chro

92 isorder (PTLD) are those who acquire primary Epstein-Barr virus (EBV) infection after solid organ tra

93 essive head and neck cancer characterized by Epstein-Barr virus (EBV) infection and dense lymphocyte

94 al carcinoma (NPC) is highly associated with Epstein-Barr virus (EBV) infection and exhibits remarkab

95 Epstein-Barr virus (EBV) infection and lytic replication

96 ene cause X-linked magnesium deficiency with Epstein-Barr virus (EBV) infection and neoplasia (XMEN),

97 A potential source of primary Epstein-Barr virus (EBV) infection for young children is

98 Epstein-Barr virus (EBV) infection in humans is a major

99 and environmental risk factors, among which Epstein-Barr virus (EBV) infection is a strong suspect.

100 Epstein-Barr virus (EBV) infection is associated with B

101 Latent Epstein-Barr virus (EBV) infection is causally linked to

102 Epstein-Barr virus (EBV) infection is ubiquitous worldwi

103 Epstein-Barr virus (EBV) infection leads to cancers with

104 Epstein-Barr virus (EBV) infection of human primary rest

105 The pathogenesis of Epstein-Barr virus (EBV) infection, including developmen

106 aryngeal carcinoma (NPC), a cancer caused by Epstein-Barr virus (EBV) infection.

107 cancer that is consistently associated with Epstein-Barr virus (EBV) infection.

108 in the disorder in Mg(2+) homeostasis after Epstein-Barr virus (EBV) infection.

109 Cytomegalovirus (CMV) and Epstein-Barr virus (EBV) infections following allogeneic

110 ch is the case for cytomegalovirus (CMV) and Epstein-Barr virus (EBV) infections of humans.

111 Epstein-Barr virus (EBV) infects greater than 90% of hum

112 Epstein-Barr Virus (EBV) infects human B cells and drive

113 Epstein-Barr virus (EBV) infects human B cells and repro

114 erial artificial chromosome (BAC).IMPORTANCE Epstein-Barr virus (EBV) infects the majority of the wor

115 Epstein-Barr virus (EBV) is a B cell transforming virus

116 s to treat EBV-associated disease.IMPORTANCE Epstein-Barr virus (EBV) is a causative agent of various

117 Epstein-Barr virus (EBV) is a common human pathogen that

118 Epstein-Barr virus (EBV) is a complex oncogenic symbiont

119 Epstein-Barr virus (EBV) is a human herpes virus that in

120 Epstein-Barr virus (EBV) is a human herpesvirus that can

121 Epstein-Barr virus (EBV) is a human tumor virus and a mo

122 Epstein-Barr virus (EBV) is a tumorigenic virus that can

123 Epstein-Barr virus (EBV) is a ubiquitous gammaherpesviru

124 Epstein-Barr virus (EBV) is a ubiquitous gammaherpesviru

125 Epstein-Barr virus (EBV) is a ubiquitous human gamma-her

126 Epstein-Barr virus (EBV) is a ubiquitous human gammaherp

127 Epstein-Barr virus (EBV) is a ubiquitous human pathogen

128 ation or its role in Zta function.IMPORTANCE Epstein-Barr virus (EBV) is a ubiquitous human pathogen

129 Epstein-Barr virus (EBV) is a ubiquitous pathogen of hum

130 Epstein-Barr virus (EBV) is a ubiquitous virus that esta

131 Epstein-Barr virus (EBV) is an enigma; on one hand, it i

132 Epstein-Barr virus (EBV) is an important human pathogen

133 Epstein-Barr virus (EBV) is an oncovirus associated with

134 The latent infection of Epstein-Barr virus (EBV) is associated with 1% of human

135 Epstein-Barr virus (EBV) is associated with a number of

136 Epstein-Barr virus (EBV) is associated with epithelial a

137 Epstein-Barr virus (EBV) is associated with multiple hum

138 The Epstein-Barr virus (EBV) is estimated to infect a large

139 Epstein-Barr virus (EBV) is implicated in the pathogenes

140 Although a pathogenic role for the Epstein-Barr virus (EBV) is largely undisputed for tumor

141 roaches to haploidentical transplantation on Epstein-Barr virus (EBV) is largely unknown.

142 Epstein-Barr virus (EBV) is one of nine human herpesviru

143 Epstein-Barr virus (EBV) is one of the most common human

144 The Epstein-Barr virus (EBV) is one of the predominant tumor

145 novel mechanisms of host control.IMPORTANCE Epstein-Barr virus (EBV) is transmitted orally, replicat

146 Epstein-Barr virus (EBV) is typically acquired asymptoma

147 program and DNA methylation state.IMPORTANCE Epstein-Barr virus (EBV) latency and carcinogenesis invo

148 Epstein-Barr virus (EBV) latency and its associated carc

149 In this study, we provide evidence that Epstein-Barr virus (EBV) latent membrane protein 1 (LMP1

150 Epstein-Barr virus (EBV) latent membrane protein-1 (LMP1

151 Epstein-Barr virus (EBV) latently infects normal B cells

152 The Epstein-Barr virus (EBV) lytic phase, like those of all

153 s: cytomegalovirus mismatch (18.5% [10/54]), Epstein-Barr virus (EBV) mismatch (EBV) (9.3% [5/54]), a

154 The viral protein Epstein-Barr virus (EBV) nuclear antigen 1 (EBNA1) binds

155 Lytic infection by the Epstein-Barr virus (EBV) poses numerous health risks, su

156 ressive lymphoid tumor which is occasionally Epstein-Barr virus (EBV) positive and is further subtype

157 n the right eye 2 months following confirmed Epstein-Barr virus (EBV) positive mononucleosis.

158 n lymphomas (HIV-NHLs), which are frequently Epstein-Barr virus (EBV) positive or human herpesvirus t

159 mor of lymphoid origin which is occasionally Epstein-Barr virus (EBV) positive.

160 Epstein-Barr virus (EBV) positivity is a feature in more

161 Epstein-Barr virus (EBV) preferentially infects epitheli

162 Epstein-Barr virus (EBV) reactivation is common in sepsi

163 Using various Epstein-Barr virus (EBV) recombinants, we provide defini

164 Recent studies reported that posttransplant Epstein-Barr virus (EBV) replication is frequent and ind

165 ect of subclinical cytomegalovirus (CMV) and Epstein-Barr virus (EBV) replication on CD4(+) and CD8(+

166 A new example is Epstein-Barr virus (EBV) ribonucleotide reductase (RNR)-

167 The lymphotropic Epstein-Barr virus (EBV) seems to avoid recognition by i

168 This study identifies an interaction between Epstein-Barr virus (EBV) SM protein and cellular helicas

169 Epstein-Barr virus (EBV) SM protein is an RNA-binding pr

170 Epstein-Barr virus (EBV) status was assessed, and 559 se

171 sequences from an enlarged set of about 200 Epstein-Barr virus (EBV) strains, including many primary

172 Epstein-Barr virus (EBV) super-enhancers (ESEs) are co-o

173 e remarkable task of lifelong infection, the Epstein-Barr virus (EBV) switches between four viral gen

174 Epstein-Barr virus (EBV) transforms B cells to continuou

175 The Epstein-Barr virus (EBV) viral glycoprotein gp350 has be

176 Epstein-Barr virus (EBV) was discovered as the first hum

177 Cytomegalovirus (CMV) and Epstein-Barr virus (EBV) were the most commonly detected

178 fically manipulate the HIV-1 genome but also Epstein-Barr virus (EBV) which, similar to KSHV, belongs

179 that recognized five common viral pathogens: Epstein-Barr virus (EBV), adenovirus (AdV), cytomegalovi

180 cellular functions, we investigated whether Epstein-Barr virus (EBV), an oncoherpesvirus, exploits i

181 s B virus (HBV), human papillomavirus (HPV), Epstein-Barr virus (EBV), and BK Virus (BKV), suggesting

182 ection of closely related DNA viruses: KSHV, Epstein-Barr virus (EBV), and herpes simplexvirus-2 (HSV

183 Cytomegalovirus (CMV), Epstein-Barr virus (EBV), and HHV-6 were shed at high ra

184 Reactivation of cytomegalovirus (CMV), Epstein-Barr virus (EBV), and varicella zoster virus (VZ

185 murine gammaherpesvirus 68 (MHV68), BGLF5 in Epstein-Barr virus (EBV), and vhs in herpes simplex viru

186 treating EBV-associated lymphomas.IMPORTANCE Epstein-Barr virus (EBV), as the first human tumor virus

187 iral response to HSV-1 and the related virus Epstein-Barr virus (EBV), as well as influenza A virus (

188 itative PCR assays of cytomegalovirus (CMV), Epstein-Barr virus (EBV), BK virus (BKV), adenovirus (AD

189 ain reaction for periodontal viruses such as Epstein-Barr virus (EBV), cytomegalovirus (CMV) and Herp

190 The 2 strains of Epstein-Barr virus (EBV), EBV type 1 (EBV-1) and EBV-2,

191 were infected with an oncogenic recombinant Epstein-Barr virus (EBV), encoding enhanced firefly luci

192 ce of known tumor-associated viruses such as Epstein-Barr virus (EBV), hepatitis B virus (HBV) and hu

193 viremia episodes with cytomegalovirus (CMV), Epstein-Barr virus (EBV), human herpesvirus 6 (HHV-6), h

194 ncogenic gammaherpesviruses, including human Epstein-Barr virus (EBV), human Kaposi's sarcoma-associa

195 are ubiquitous, and infection by some, like Epstein-Barr virus (EBV), is nearly universal.

196 The human DNA tumor viruses Epstein-Barr virus (EBV), Kaposi's sarcoma-associated he

197 re, we show that the large dsDNA herpesvirus Epstein-Barr virus (EBV), which is the causative agent o

198 n follicular helper T cells (TFH cells), and Epstein-Barr virus (EBV), which persists in B cells.

199 Most humans become infected with Epstein-Barr virus (EBV), which then persists for life.

200 Epstein-Barr virus (EBV)-associated diseases of epitheli

201 ized by lymphocytic defects with early-onset Epstein-Barr virus (EBV)-associated lymphoma.

202 s), is an appealing therapeutic approach for Epstein-Barr virus (EBV)-associated malignancies of late

203 Several therapeutic strategies targeting Epstein-Barr virus (EBV)-associated tumors involve upreg

204 rs the formation of PDX tumors that resemble Epstein-Barr virus (EBV)-driven B-cell lymphomas rather

205 Lymphomatoid granulomatosis (LYG) is a rare Epstein-Barr virus (EBV)-driven B-cell lymphoproliferati

206 triggered by the gly-ala repeat sequence of Epstein-Barr virus (EBV)-encoded EBNA1, results in PI3Kd

207 Latent membrane protein 1 (LMP1) is an Epstein-Barr virus (EBV)-encoded oncoprotein that is pac

208 ite advances in T-cell immunotherapy against Epstein-Barr virus (EBV)-infected lymphomas that express

209 cause a T-cell primary immunodeficiency with Epstein-Barr virus (EBV)-lymphoproliferative disorders.

210 More than 70% of Epstein-Barr virus (EBV)-negative Hodgkin lymphoma (HL)

211 enomes in blood and tissue infiltration with Epstein-Barr virus (EBV)-positive lymphocytes.

212 ty-two cytomegalovirus (CMV)-positive and 41 Epstein-Barr virus (EBV)-positive plasma samples, togeth

213 sed throughout infection, can be detected in Epstein-Barr virus (EBV)-positive tumors, and manipulate

214 edominantly manifesting as susceptibility to Epstein-Barr virus (EBV)-related diseases.

215 vely, detected in cytomegalovirus (CMV)- and Epstein-Barr virus (EBV)-responsive CD4+ T cells followi

216 ncies for influenza-specific (A2/M1(58)) and Epstein-Barr virus (EBV)-specific (A2/BMLF(1280)) (~1.38

217 reinvigorated by the implementation of novel Epstein-Barr virus (EBV)-specific IgA and IgG antibodies

218 nt of LUBAC, interacts with LMP1 and IRF7 in Epstein-Barr virus (EBV)-transformed cells and that LUBA

219 d by the latent membrane protein 1 (LMP1) of Epstein-Barr virus (EBV).

220 s initially were seeded by single genomes of Epstein-Barr virus (EBV).

221 s (KSHV) and 86% of PELs are coinfected with Epstein-Barr virus (EBV).

222 gent, and ~80% of tumors are coinfected with Epstein-Barr virus (EBV).

223 pic gamma-herpesvirus closely related to the Epstein-Barr virus (EBV).

224 adenylated isoform structures in replicating Epstein-Barr virus (EBV).

225 to autologous B cells latently infected with Epstein-Barr virus (EBV).

226 V2), and another compound was active against Epstein-Barr virus (EBV).

227 Africa, is distinguished by its inclusion of Epstein-Barr virus (EBV).

228 reptococcus mutans, and Human herpesvirus 4 (Epstein-Barr virus [EBV]) were more prevalent in childre

229 infections (i.e., cytomegalovirus [CMV] and Epstein-Barr virus [EBV]).

230 al infections (HIV, hepatitis C virus [HCV], Epstein-Barr virus [EBV], and cytomegalovirus [CMV]) hav

231 to control antigens (cytomegalovirus [CMV], Epstein-Barr virus [EBV], and influenza virus [FLU]) or

232 ADV], BK virus [BKV], cytomegalovirus [CMV], Epstein-Barr virus [EBV], human herpesvirus 6A [HHV-6A],

233 titis B core [HBc], hepatitis C virus [HCV], Epstein-Barr virus [EBV], or cytomegalovirus [CMV]) in K

234 CD10, BCL6, perforin, TIA-1, Granzyme B and Epstein-Barr virus-encoded RNA.

235 rom both adenovirus-associated (VA) RNAs and Epstein-Barr virus-encoded small RNAs (EBERs) with respe

236 lyssavirus, herpes simplex viruses 1 and 2, Epstein-Barr virus, enterovirus, cytomegalovirus, and ch

237 ctors included a high prevalence of previous Epstein-Barr virus exposure and a relatively low immunol

238 globulin plus GVHD prophylaxis group died of Epstein-Barr virus hepatitis, but no deaths were attribu

239 Samples were investigated for Epstein-Barr virus, herpes simplex virus, and HCMV-speci

240 Here we used iPSCs derived from Epstein-Barr virus-immortalized B-lymphocytes to verify

241 type) or BGLF5 (the KSHV protein homolog in Epstein-Barr virus) in 293L/Q129H cells restored the vir

242 positive test results for cytomegalovirus or Epstein-Barr virus, indicating possible cross-reactivity

243 Here, we show that Epstein-Barr virus-induced 3 (EBI3) is expressed by huma

244 ll migration, the G protein-coupled receptor Epstein-Barr virus-induced gene 2 (EBI2 or GPR183) direc

245 rphan G-protein-coupled receptors, including Epstein-Barr virus-induced gene 2 (EBI2).

246 sions: In COPD lungs, we found lung EBI2(+) (Epstein-Barr virus-induced gene 2-positive) OX-40L-expre

247 Epstein-Barr virus-induced gene 3 (EBI3) is a subunit of

248 se that expressed the extrafollicular marker Epstein-Barr virus-induced protein 2 (EBI2), but signifi

249 report that in human airway epithelial cells Epstein-Barr virus induces TRIM29, a member of the TRIM

250 Epstein-Barr virus infection has a role in the pathogene

251 s, such as the incidence of acute rejection, Epstein-Barr virus infection, sepsis, biliary and vascul

252 Genomic lesions, Epstein-Barr virus infection, soluble factors, and tumor

253 is based on false-positive tests for primary Epstein-Barr virus infection.

254 oped cervical adenopathy, being diagnosed of Epstein-Barr virus infectious mononucleosis.

255 Epstein-Barr virus infects B-cells and epithelial cells,

256 xic effects of Zta overexpression.IMPORTANCE Epstein-Barr virus infects most people across the world

257 nt for diverse functions of EBNA1.IMPORTANCE Epstein-Barr virus is a human gammaherpesvirus that is c

258 trategies in the clinical setting.IMPORTANCE Epstein-Barr virus is associated with many different can

259 Epstein-Barr virus is associated with several human mali

260 r efficient viral DNA replication.IMPORTANCE Epstein-Barr virus is the causative agent of infectious

261 Epstein-Barr Virus latent membrane protein-1 (LMP1) inte

262 s in the blood of patients with myocarditis: Epstein Barr virus (n=11, 41%), human pegivirus (n=1, 4%

263 s B virus (n = 10), cytomegalovirus (n = 9), Epstein-Barr virus (n = 5), and rotavirus A (n = 3) were

264 B virus (n = 2), human pegivirus 1 (n = 2), Epstein-Barr virus (n = 9), and Orungo virus (n = 1), a

265 n vIRF1, which is identical to that found in Epstein-Barr virus nuclear antigen 1 (EBNA1) that intera

266 ting tumor cells requires the interaction of Epstein-Barr virus nuclear antigen 1 (EBNA1) with the vi

267 on factor 2) bound cooperatively with EBNA1 (Epstein-Barr virus nuclear antigen 1) at OriP.

268 es to the host cell nucleolus where it binds Epstein-Barr virus nuclear antigen 1-binding protein 2 (

269 In studying Epstein-Barr virus, one of the most prevalent human herp

270 utologous VSTs specific for cytomegalovirus, Epstein-Barr virus, or adenovirus and genetically modifi

271 cells with specificity for cytomegalovirus, Epstein-Barr virus, or influenza virus.

272 y cutaneous acral CD8(+) T-cell lymphoma and Epstein-Barr virus positive (EBV(+)) mucocutaneous ulcer

273 Epstein-Barr virus-positive (EBV+) diffuse large B-cell

274 Epstein-Barr virus proteins EBNA3A, EBNA3B and EBNA3C co

275 Clinically significant Epstein-Barr virus reactivation (EBV-R) following AHSCT

276 Epstein-Barr virus reactivation was substantially more c

277 T-cell lymphotrophic virus 1 expression, and Epstein-Barr virus reactivation.

278 Cytomegalovirus and Epstein-Barr virus reactivations were well controlled, b

279 memory T cells from the related herpesvirus Epstein-Barr virus remained undetectable.

280 tes EBV reactivation from latency.IMPORTANCE Epstein-Barr virus represents an important human pathoge

281 element (HRE) located within the promoter of Epstein-Barr virus's (EBV's) latent-lytic switch BZLF1 g

282 bodies (aIRR = 2.03); in recipients who were Epstein-Barr virus-seronegative at the time of transplan

283 Here we show that expression of the Epstein-Barr virus signalling protein LMP1 in B cells pr

284 he atomic structure of the portal protein of Epstein-Barr virus, solved by cryo-electron microscopy a

285 ion marker CD57, and fewer HDV-specific than Epstein-Barr virus-specific CD8(+) T cells were 2B4(+)CD

286 We also identified Epstein-Barr virus-specific T cell receptors and EBV(+)

287 ed, which also affected cytomegalovirus- and Epstein-Barr virus-specific T cells.

288 o their histology, microsatellite stability, Epstein-Barr virus status, and molecular profile.

289 P), and others such as NLRC4, CDC42, and the Epstein-Barr virus susceptibility diseases.

290 h repair protein expression or expression of Epstein-Barr virus transcripts.

291 HLA-A*02:01 and HLA-B*27:05 expressed on the Epstein-Barr virus-transformed B cell line Jesthom and M

292 In Epstein-Barr virus-transformed lymphocytes derived from

293 sequencing and protein expression assays in Epstein-Barr virus-transformed lymphocytes.

294 HSV UL37 with the human cytomegalovirus and Epstein-Barr virus UL37 homologs revealed that Y480 was

295 natural killer clone in response to chronic Epstein-Barr virus viremia.

296 No viral transcripts, including from Epstein-Barr virus, were detected.

297 iherpesviral and anticancer drugs.IMPORTANCE Epstein-Barr virus, which is nearly ubiquitous in humans

298 virus type 1, human herpesvirus type 6, and Epstein-Barr virus) with change in leukocyte telomere le

299 viral infections with human herpesvirus 6 or Epstein-Barr virus within 100 days after transplant incr

300 Epstein-Barr Virus Zta is a key transcriptional regulato